BAP1 Mutation

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Clear Cell Renal Cell Carcinoma3
BAP1 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	5	accepted	EID459 In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type. PMID 23797736 · Sato et al., 2013 · Open in CIViC	civic
BAP1 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	5	accepted	EID461 In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type. PMID 23792563 · 2013, Nature · Open in CIViC	civic
BAP1 Mutation	Everolimus + SunitinibSequential

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Clear Cell Renal Cell Carcinoma3

BAP1 Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID459

In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type.

PMID 23797736 · Sato et al., 2013 · Open in CIViC

civic

BAP1 Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID461

In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type.

PMID 23792563 · 2013, Nature · Open in CIViC

civic

BAP1 Mutation

Everolimus + SunitinibSequential

Malignant Mesothelioma3
BAP1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11740 In this study, 23 patients with refractory mesothelioma harbouring germline or somatic BAP1 mutations were treated with olaparib. The median PFS was 3.6 months (95% CI, 2.7-4.2), and the median OS was… (full text at CIViC) PMID 34661178 · Ghafoor et al., 2021 · Open in CIViC	civic
BAP1 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11741 In this study, 23 patients with refractory mesothelioma harbouring germline or somatic BAP1 mutations were treated with olaparib. The median PFS was 3.6 months (95% CI, 2.7-4.2), and the median OS was… (full text at CIViC) PMID 34661178 · Ghafoor et al., 2021 · Open in CIViC	civic
BAP1 Mutation OR NF2 Mutation OR SETD2 Mutation	Samotolisib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11742 In this study, 42 patients with malignant pleural or peritoneal mesothelioma were treated with single-agent LY3023414 (Samotolisib). Among the 42 patients, 11 had BAP1 mutations, while SETD2 and NF2 m… (full text at CIViC) PMID 33660194 · Zauderer et al., 2021 · Open in CIViC	civic

Malignant Mesothelioma3

BAP1 Mutation

Olaparib

Predictive

Supports Sensitivity Response

submitted

EID11740

In this study, 23 patients with refractory mesothelioma harbouring germline or somatic BAP1 mutations were treated with olaparib. The median PFS was 3.6 months (95% CI, 2.7-4.2), and the median OS was… (full text at CIViC)

PMID 34661178 · Ghafoor et al., 2021 · Open in CIViC

civic

BAP1 Mutation

Olaparib

Predictive

Supports Sensitivity Response

submitted

EID11741

PMID 34661178 · Ghafoor et al., 2021 · Open in CIViC

civic

BAP1 Mutation OR NF2 Mutation OR SETD2 Mutation

Samotolisib

Predictive

Supports Sensitivity Response

submitted

EID11742

In this study, 42 patients with malignant pleural or peritoneal mesothelioma were treated with single-agent LY3023414 (Samotolisib). Among the 42 patients, 11 had BAP1 mutations, while SETD2 and NF2 m… (full text at CIViC)

PMID 33660194 · Zauderer et al., 2021 · Open in CIViC

civic

Pleural Malignant Mesothelioma1
BAP1 Mutation	CDK4/6 Inhibition	Predictive	D	Supports Sensitivity Response	4	submitted	EID12008 The effect of CDK4/6 inhibitors (abemaciclib or palbociclib) was tested in patient-derived malignant pleural mesothelioma (MLM) cell lines. Of the three patient-derived cell lines, two of the cell lin… (full text at CIViC) PMID 34588615 · Aliagas et al., 2021 · Open in CIViC	civic

Pleural Malignant Mesothelioma1

BAP1 Mutation

CDK4/6 Inhibition

Predictive

Supports Sensitivity Response

submitted

EID12008

The effect of CDK4/6 inhibitors (abemaciclib or palbociclib) was tested in patient-derived malignant pleural mesothelioma (MLM) cell lines. Of the three patient-derived cell lines, two of the cell lin… (full text at CIViC)

PMID 34588615 · Aliagas et al., 2021 · Open in CIViC

civic

Renal Cell Carcinoma1
BAP1 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	5	accepted	EID460 In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type. PMID 23797736 · Sato et al., 2013 · Open in CIViC	civic

Renal Cell Carcinoma1

BAP1 Mutation

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID460

In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type.

PMID 23797736 · Sato et al., 2013 · Open in CIViC

civic

Uveal Melanoma1
BAP1 Mutation	Panobinostat + Trichostatin A + Valproic Acid + VorinostatSubstitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID1234 Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanom… (full text at CIViC) PMID 22038994 · Landreville et al., 2012 · Open in CIViC	civic

Uveal Melanoma1

BAP1 Mutation

Panobinostat + Trichostatin A + Valproic Acid + VorinostatSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID1234

Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanom… (full text at CIViC)

PMID 22038994 · Landreville et al., 2012 · Open in CIViC

civic

Evidence by cancer (9 items)

Clinical significance (0)